Table 6 Sources of evidence to estimate resource use
Author, year | Parameters used in studies | Data source | Age of target population | Mean age of estimation sample |
|---|---|---|---|---|
Direct cost | ||||
Treatments Adjuvant chemo alone (CMF) Adjuvant chemo alone (AC) Adjuvant endocrine alone (Tamoxifen) Adjuvant Chemo (CMF) + Tamoxifen Adjuvant Chemo (AC) + Tamoxifen | Published guidelines, research studies, and expert opinion of the treatment. Managing side effects of adjuvant chemotherapy from clinical trials [45] | 45 years 65 years 75 years 85 years | Not reported | |
Skedgel et al. (2013) [21] | Treatment TC course FEC-D course 12 months adjuvant trastuzumab, per case Health states Local recurrence, per case Distant recurrence, per case Post-recurrence follow-up, per month Side effect Febrile neutropenia, per case AML/MDS, per month Chemo-related CHF, per month Chemo-related nausea and vomiting, per case Trastuzumab-related cardiotoxicity, per month Palliative trastuzumab, per case | TC course, FEC-D course, febrile neutropenia, AMD/MDS, and chemo related nausea and vomiting from previous literature [72, 73], 12 months adjuvant trastuzumab from previous literature [75], local recurrence, distant recurrence and post-recurrence follow-up from previous literature [47], chemo-related CHF from previous cost-effectiveness analysis [76], and palliative trastuzumab from literature [77] | 40 years 50 years 60 years 70 years 80 + years | Not reported |
Sen et al. (2014) [20] | Treatments No RT EBRT IMRT Brachytherapy Health states Recurrence, mastectomy Metastatic care Continued phase Death, last year of life | SEER-Medicare Previous costing study [78] | 70, 75, and 80 years | 70–74 years; 75–79 years; 80–94 years |
Desch et al. (1993)Â [24] | Health states Chemotherapy, if given Side effects Minor toxicity Major toxicity | Medical College of Virginia and estimates from Medicare data (1989) | 60Â years 65Â years 70Â years 75Â years 80Â years | Not reported |
Direct and indirect cost | ||||
Treatments Radiation Therapy Anastrozole (per year) Indirect costs of RT Indirect costs of Endocrine Therapy (Annual) Health states Salvage Mastectomy Salvage Lumpectomy or Axillary Dissection Metastatic Disease (per year) | ASCO and National Cancer Centers Network (NCCN) guidelines, all costs were adjusted to 2019 dollars using the US Bureau of Labor Statistics overall Consumer Price Index inflation | 70Â years or older | Not reported | |